Tuesday, December 3, 2013

23andMe Genetic Testing

Alberto Gutierrez
Center for Devices and Radiological Health
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear Mr. Gutierrez,

I’ve recently learned that the FDA has determined the genetic test kit from 23andMe are “intended for use in the diagnosis…” as per 21 U.S.C. 321(h).   Does the FDA truly think the public will take a $99 test and use it as the sole basis for self-diagnoses?

“… if the BRCA-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery…”

It seems your office believes women wouldn’t consult their physician when alerted by this test and or physicians wouldn’t seek confirmation before prophylactic surgery.  Are you kidding?  I’ve read your recent letter to 23andMe and your argument is flawed and goes against the mission of the FDA:

“… responsible for advancing the public health by helping to speed innovations that make medicines more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medicines and foods to maintain and improve their health.”

Regardless of spin you are essentially banning affordable genetic screening.  Your actions have consequences and history will be your judge.  I spent four hundred dollars to get my family tested.  Had that cost been just 50% more I wouldn’t have done it.  Requiring premarket approval for genetic screening will further destroy this fledgling industry and is NOT aligned with the rapidly changing technology of this field.

Your letter states that you have conducted 14 face-to-face and teleconference meetings, sent hundreds of emails, and dozens of letters.  Which begs the question - was 23andMe at those meetings and responding to your emails and letters?  Clearly 23andMe isn’t trying to avoid the FDA and their use of CLIA certified labs indicates they have taken steps to comply with FDA guidelines.

While false positives have consequences that I’ve personally witnessed the net benefit of mass screenings is too great to ignore and I couldn’t imagine a more effective way to rapidly determine accuracy than to let the testing proceed with a strong “Surgeon General’s” like warning that the results are preliminary.

Sincerely,

Dave